EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

A dose scaling antivenin protocol in treatment of Daboia palaestinae envenomation may reduce morbidity and costs

Daniel J Jakobson iD, Zurab Zakariashvili, Enzo F Galicia H, Mohammad Abu Issa, Miguel M Glatstein, Frederic S Zimmerman iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0319119 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift PLOS One, 2025. Verfasst von Daniel J Jakobson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Intensive Care Department, Barzilai University Medical Center, Ashkelon, Israel. Hauptthemen laut MEDLINE: Snake Bites, Antivenins, Daboia. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Daboia palaestinae is a leading cause of snakebite envenomation in the eastern Mediterranean, with substantial mortality in the absence of antivenin. Current recommended antivenin dose is 50 ml; however, antivenin is costly, may be difficult to obtain and is associated with substantial side effects. Thus, this study was designed to define the minimal effective antivenin dose and identify patients who can be safely managed without antivenin.

Methods

This retrospective single-center study was conducted in adults with suspected or confirmed D. palaestinae envenomation. Patients were treated via our previously developed envenomation protocol: no antivenin use for local symptoms and dose scaling for mild or severe systemic symptoms – initially 10 ml antivenin, with repeat dosing for ongoing systemic symptoms. The main outcomes measured were morbidity and mortality associated with this protocol. Secondary outcomes included assessing the demographics and clinical effects of snake envenomation and comparing between those who received antivenin and those who did not.

Results

In total, 101 patients were included. A median of 45 minutes [interquartile range: 30–61 minutes] elapsed between snakebite and hospital admission, with no differences between groups. Among 52 patients receiving antivenin, 119 [60–237] minutes elapsed between snakebite and initial antivenin administration, with a maximum of 1073 minutes to initial antivenin administration. Maximum until last antivenin was 3860 minutes. Median antivenin dose was 15 [10–22.5] ml, with 26/52 (50.0%) requiring only 10 ml. Two (2) patients developed an early antivenin immune reaction, with one developing anaphylaxis requiring invasive ventilation. Both received a single 10 ml dose of antivenin prior to allergic reaction. Neither patient had a known history of exposure to serum or relevant allergic reaction. No patients died during hospitalization.

Conclusions

This cohort demonstrates that a dose-scaling antivenin protocol can be safely employed, reducing morbidity and costs. We recommend a randomized control trial comparing fixed dose regimen to an escalation protocol and development of similar protocols for envenomations due to other snake species.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Snake BitesAntiveninsDaboiaHumansMaleFemaleAnimalsRetrospective StudiesMiddle AgedAdultAgedTreatment Outcome

Substanzen

Antivenins

Autor:innen und Institutionen

  • Intensive Care Department, Barzilai University Medical Center, Ashkelon, Israel.
  • Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheba, Israel.
  • Department of Anesthesiology, Barzilai University Medical Center, Ashkelon, Israel.
  • Division of Pediatric Emergency Medicine, Dana-Dwek Children's Hospital, School of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Division of Clinical Pharmacology and Toxicology, Ichilov Hospital, Tel Aviv University, Tel Aviv, Israel.

ORCID-Profile: Daniel J Jakobson, Frederic S Zimmerman

Zitieren

APA

Jakobson, D. J., Zakariashvili, Z., Galicia H, E. F., Abu Issa, M., Glatstein, M. M., & Zimmerman, F. S. (2025). A dose scaling antivenin protocol in treatment of Daboia palaestinae envenomation may reduce morbidity and costs. PLOS One. https://doi.org/10.1371/journal.pone.0319119

Vancouver

Jakobson DJ, Zakariashvili Z, Galicia H EF, Abu Issa M, Glatstein MM, Zimmerman FS. A dose scaling antivenin protocol in treatment of Daboia palaestinae envenomation may reduce morbidity and costs. PLOS One. 2025. doi:10.1371/journal.pone.0319119

BibTeX
@article{Jakobson2025,
  author = {Jakobson, Daniel J and Zakariashvili, Zurab and Galicia H, Enzo F and Abu Issa, Mohammad and Glatstein, Miguel M and Zimmerman, Frederic S},
  title = {A dose scaling antivenin protocol in treatment of Daboia palaestinae envenomation may reduce morbidity and costs},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0319119}
}
Kostenlos starten →